SG3 Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-161,000
Closed -$9.57M 557
2022
Q1
$9.57M Buy
161,000
+30,700
+24% +$1.96M 0.27% 88
2021
Q4
$9.46M Buy
130,300
+34,900
+37% +$2.4M 0.19% 99
2021
Q3
$6.66M Buy
95,400
+58,000
+155% +$4.07M 0.2% 98
2021
Q2
$2.58M Sell
37,400
-30,000
-45% -$2M 0.09% 255
2021
Q1
$4.36M Buy
67,400
+47,400
+237% +$3.06M 0.11% 205
2020
Q4
$1.17M Buy
20,000
+10,000
+100% +$603K 0.02% 524
2020
Q3
$632K Sell
10,000
-40,000
-80% -$2.77M 0.02% 507
2020
Q2
$3.85M Buy
50,000
+200
+0.4% +$15.3K 0.27% 91
2020
Q1
$3.72M Buy
+49,800
New +$3.44M 0.5% 37
2019
Q3
Sell
-30,000
Closed -$2.03M 375
2019
Q2
$2.03M Buy
+30,000
New +$1.97M 0.22% 90
2017
Q3
Sell
-14,800
Closed -$1.05M 203
2017
Q2
$1.05M Buy
+14,800
New +$985K 0.26% 95
2017
Q1
Sell
-19,500
Closed -$1.4M 265
2016
Q4
$1.4M Buy
+19,500
New +$1.45M 0.23% 77

Other funds holding GILD

SG3 Management's GILD Position: Q2 2022 in Review

SG3 Management sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 5,500 shares — an estimated $327K sold.

SG3 Management first reported a position in GILD in Q3 2020 and held it in 6 quarters. The position peaked at $2M in Q4 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

  • SG3 Management reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 5,500 Gilead Sciences shares in Q2 2022, an estimated $327K.
  • SG3 Management first reported a position in Gilead Sciences in Q3 2020 and held it in 6 quarters.
  • SG3 Management's Gilead Sciences position peaked at $2M in Q4 2021.
  • 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.